Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.46 USD
+0.15 (3.48%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.46 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Aquestive Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 24 | 27 | 28 | 32 | 49 |
Receivables | 8 | 5 | 12 | 7 | 13 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 7 | 6 | 4 | 2 | 3 |
Other Current Assets | 2 | 2 | 3 | 3 | 3 |
Total Current Assets | 41 | 40 | 47 | 45 | 68 |
Net Property & Equipment | 4 | 4 | 5 | 7 | 10 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1 | 1 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 6 | 7 | 8 | 0 |
Total Assets | 57 | 57 | 62 | 63 | 78 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 10 | 8 | 7 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 8 | 9 | 9 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 21 | 4 | 5 | 1 |
Total Current Liabilities | 18 | 40 | 22 | 21 | 19 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 32 | 31 | 7 | 4 | 4 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 28 | 33 | 52 | 34 | 60 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 80 | 66 | 62 | 49 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 164 | 176 | 144 | 111 | 85 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 213 | 193 | 175 | 138 | 124 |
Retained Earnings | -319 | -311 | -257 | -186 | -130 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -106 | -119 | -82 | -49 | -6 |
Total Liabilities & Shareholder's Equity | 57 | 57 | 62 | 63 | 78 |
Total Common Equity | -106 | -119 | -82 | -49 | -6 |
Shares Outstanding | 66.70 | 54.10 | 40.10 | 34.50 | 33.50 |
Book Value Per Share | -1.60 | -2.19 | -2.05 | -1.41 | -0.18 |
Fiscal Year End for Aquestive Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 90 | 95 | 24 | 25 | 22 |
Receivables | 6 | 8 | 8 | 9 | 10 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 7 | 8 | 7 | 7 | 6 |
Other Current Assets | 1 | 2 | 2 | 2 | 1 |
Total Current Assets | 104 | 113 | 41 | 42 | 40 |
Net Property & Equipment | 4 | 4 | 4 | 5 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 1 | 1 | 1 | 1 |
Deposits & Other Assets | 4 | 5 | 5 | 5 | 5 |
Total Assets | 118 | 130 | 57 | 59 | 57 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 11 | 9 | 10 | 11 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 5 | 7 | 5 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 2 | 8 | 23 |
Total Current Liabilities | 14 | 18 | 18 | 24 | 39 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 22 | 32 | 32 | 33 | 33 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 30 | 29 | 28 | 35 | 21 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 82 | 80 | 66 | 65 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 153 | 166 | 164 | 162 | 164 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 299 | 296 | 213 | 208 | 202 |
Retained Earnings | -335 | -332 | -319 | -311 | -309 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -35 | -36 | -106 | -103 | -107 |
Total Liabilities & Shareholder's Equity | 118 | 130 | 57 | 59 | 57 |
Total Common Equity | -35 | -36 | -106 | -103 | -107 |
Shares Outstanding | 91.00 | 91.00 | 66.70 | 66.70 | 55.90 |
Book Value Per Share | -0.39 | -0.40 | -1.60 | -1.54 | -1.91 |